Effect of Prone Positioning in Patients With COVID-19

May 12, 2025 updated by: Sialkott College of Physical Therapy

Effect of Prone Positioning and Alternate Nostril Breathing Technique in Patients With COVID-19: A Quasi Experimental Study.

COVID-19 is affecting the people around the world and the infected individuals' may either stay asymptomatic or present to hospitals with severe distress and life threatening symptoms. The objective of the study is to investigate role of Prone positioning and alternate nostril breathing in patients with Covid-19.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

In this quasi experimental study, 30 patients aged 40-80 years of either gender with a confirmed diagnosis of COVID-19 receiving supplemental oxygen were recruited from DHQ Hospital Faisalabad. patients were grouped into two A & B. We collected baseline data on demographics and anthropometrics. After baseline data collection, all the patients were helped into the prone position, which was maintained for a minimum duration of three hours. After that patients in group B performed alternate nostril breathing for 10 minutes with help of physiotherapist. Clinical data were re-collected on 3rd day of intervention one hour after returning to the supine position in group A and after alternate nostril breathing in group B. The main study outcome was the variation in oxygenation (partial pressure of oxygen [PaO2]/ fractional concentration of oxygen in inspired air [FiO2]) between baseline and resupination, and General psychological state through GAD-7 General anxiety disorder questionnaire.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab
      • Faisalabad, Punjab, Pakistan, 38000
        • DHQ Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Study Population

known cases of Covid-19 who were hospitalized.

Description

Inclusion Criteria:

Age: 40-80 Gender: Both GCS score:15

Exclusion Criteria:

  • COPD Intubated ARDS Smoker Neurological Disorder

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group-A
Patient performed prone lying position for three hours.
Other: Prone Lying Position
patient lies on his/ her stomach facing floor.
Other Names:
  • Positioning
Active Comparator: Group-B
along with Prone lying position, patients also performed alternate nostril breathing for ten minutes.
Other: Prone Lying Position
patient lies on his/ her stomach facing floor.
Other Names:
  • Positioning
Other: alternate nostril breathing
patient inspires with one nostril at a time, right or left one by one and expires by mouth.
Other Names:
  • breathing technique

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PaO2
Time Frame: Change in score before the intervention on 1st day of intervention and on 3rd day one hour after the intervention.
partial pressure of oxygen.
Change in score before the intervention on 1st day of intervention and on 3rd day one hour after the intervention.
FiO2
Time Frame: Change in score before the intervention on 1st day of intervention and on 3rd day one hour after the intervention.
Fractional concentration of oxygen in inspired air [FiO2])
Change in score before the intervention on 1st day of intervention and on 3rd day one hour after the intervention.
General Anxiety Disorder-7 Score
Time Frame: Change in score before the intervention on 1st day of intervention and on 3rd day one hour after the intervention.
general anxiety disorder-7 score ranges from 0-21, out of which 0-4 means minimal anxiety, 5-9 stands for mild anxiety, 10-14 for moderate and 15-21 for severe anxiety.
Change in score before the intervention on 1st day of intervention and on 3rd day one hour after the intervention.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sialkott College of Physical Therapy

Investigators

  • Principal Investigator: Sahreen Anwar, PhD, Independent Medical College, Faisalabad

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 23, 2020

Primary Completion (Actual)

January 15, 2021

Study Completion (Actual)

January 29, 2021

Study Registration Dates

First Submitted

January 9, 2021

First Submitted That Met QC Criteria

January 13, 2021

First Posted (Actual)

January 15, 2021

Study Record Updates

Last Update Posted (Actual)

May 15, 2025

Last Update Submitted That Met QC Criteria

May 12, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 138-2020

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

there is a plan to share IPD.

IPD Sharing Time Frame

after completion of study for one year.

IPD Sharing Access Criteria

via direct email to PI.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid19

Clinical Trials on Prone Lying Position

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe